+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.

Age: 18Years +All GendersPhase 3
217 locations
O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
O

Actively Recruiting

Researchers are observing patients with documented HER2-positive, HER2-low, or HER2-ultralow unresectable or metastatic breast cancer who are receiving trastuzumab deruxtecan T-DXd treatment. The study evaluates patient-reported outcomes as well as real-world effectiveness and safety of T-DXd when used according to the approved product guidelines within routine clinical practice in Germany. Additionally, patients will be informed about using a digital healthcare application DiGA. Participants receive T-DXd treatment as part of their routine care, with no specific treatment schedule dictated by the study protocol. The study includes two groups one with HER2-positive breast cancer patients and another with HER2-low or HER2-ultralow patients, each group expected to enroll approximately 400 participants. All diagnostic and treatment decisions, including visit frequency, are managed by the treating physician. During the study, participants health and treatment progress will be tracked, including patient-reported quality of life assessments using FACT-B and FACT-G questionnaires at six months. Researchers will monitor the time from first T-DXd dose to the next treatment or death, assessed for up to 60 months. The study lasts until December 2031, with ongoing observation of real-world treatment outcomes and safety.

Age: 18Years - 130YearsAll Genders
109 locations
O

Actively Recruiting

Researchers are evaluating how well cabozantinib works and how safe it is for adults with neuroendocrine tumors NETs, a type of cancer that can appear in various parts of the body. This study is focused on adults whose disease has continued to grow despite receiving at least one prior systemic treatment. The study takes place in regular hospitals and clinics in Germany and Austria and involves about 150 participants. Participants in this observational study will be taking cabozantinib as part of their usual care. No extra tests or procedures beyond routine medical visits, tests, and scans will be performed. Doctors will collect information on how the cancer responds to cabozantinib and how long participants stay on the treatment, along with monitoring side effects and quality of life. During the study, participants will be observed through their standard medical care visits. Researchers will gather data from routine medical tests, scans, and questionnaires about quality of life every three months for up to 18 months. They will measure disease control rates at 6 months, treatment duration, adverse events, and other clinical outcomes. The total follow-up period can last up to 18 months to monitor disease progression and treatment impact.

Age: 18Years +All Genders
41 locations
O

Actively Recruiting

Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines. Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies. During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.

Age: 18Years +All Genders
74 locations